Artelo Biosciences Stock News

Artelo Biosciences Inc (ARTL) shares closed 1.1% lower than its previous 52 week low, giving the company a market cap of $23M. The stock is currently down 22.8% year-to-date, down 11.3% over the past 12 months, and down 87.9% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 27.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Consumer Discretionary industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -24.4% The company's stock price performance over the past 12 months beats the peer average by -63.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

HC Wainwright reaffirmed their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research report released on Tuesday, TipRanks reports. The brokerage currently has a $4.00 price target on the stock. Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Artelo Biosciences from a sell []

$26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023 $26.8 Million in Cash and Marketable Securities as of November 15, 2021, Expected to Support Operations Well Into 2023

Renaissance Technologies LLC purchased a new position in Artelo Biosciences, Inc. (NASDAQ:ARTL) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 556,738 shares of the companys stock, valued at approximately $663,000. Renaissance Technologies LLC owned approximately 2.27% of Artelo Biosciences at []

Analysts expect that Artelo Biosciences, Inc. (NASDAQ:ARTL) will post earnings of ($0.10) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Artelo Biosciences’ earnings. Artelo Biosciences reported earnings of ($0.20) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. […]

Solana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signa

Are these penny stocks on your watchlist this week? The post Best Penny Stocks to Watch in Mid-November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check these trending penny stocks out for your watchlist The post Are These Trending Penny Stocks Worth Buying at Current Levels? appeared first on Penny Stocks to Buy, Picks, News and Information | P

Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) increased by over 60% pre-market today. This is why it happened.

Artelo Biosciences, Inc. (ARTL) Q3 2021 Results - Earnings Call Transcript

Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that targe

Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD

LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end